What is the current market size?

The Toxicology Drug Screening market size was valued at USD 1.2 billion in 2023, driven by rising demand for workplace and clinical drug testing.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, fueled by advancements in point-of-care testing technologies.

What are key market drivers?

Key drivers include increasing prevalence of substance abuse, stringent workplace safety regulations, and expansion into emerging markets.

What challenges does the market face?

High testing costs, stringent regulatory compliance, and ethical concerns over privacy and consent hinder market growth.

Which regions lead the market?

North America dominates the market due to robust healthcare infrastructure, followed by Europe and Asia-Pacific regions.

Who are the top companies?

Leading firms include Thermo Fisher Scientific, Quest Diagnostics, and PerkinElmer, known for innovation in drug screening solutions.

What future opportunities exist?

Opportunities lie in expanding geriatric populations, growing adoption in sports and law enforcement, and partnerships for R&D.

How is technology impacting the market?

AI-driven analytics, portable testing devices, and lab-on-a-chip technologies are revolutionizing accuracy and accessibility.

What is the regulatory landscape?

Regulatory bodies like FDA and WHO enforce strict quality standards, ensuring test reliability while encouraging innovation.

Toxicology Drug Screening Market Comprehensive Report: 200+ Pages | 2026–2034

Toxicology Drug Screening by Application (Hospitals, Clinics, Laboratory, Others), by Types (Cardiovascular Disease Drug Screening, Obesity Drug Screening, Diabetes Drug Screening, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Toxicology Drug Screening Market Size | CAGR 7.5 Forecast 2033

Toxicology Drug Screening Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Toxicology Drug Screening Market Overview

The Toxicology Drug Screening market encompasses diagnostic solutions for detecting and quantifying drugs in biological samples to support clinical, forensic, and workplace safety applications. With rising prevalence of substance abuse, regulatory mandates, and advancements in diagnostic technologies, this market is a critical component of global healthcare and compliance infrastructures. The Toxicology Drug Screening market size is projected to exceed $2.4 billion by 2033, reflecting a CAGR of 6.8% during the forecast period (2026–2033). Key drivers include expanding applications in pain management monitoring, workplace drug testing, and opioid crisis mitigation, alongside innovation in rapid, point-of-care testing platforms.

Loading chart…

The market is shaped by technological innovation, such as AI-integrated screening systems for faster result turnaround, and regulatory tailwinds, including FDA approvals for novel assay formats. While North America dominates the market due to high adoption rates and mature healthcare frameworks, Asia-Pacific is emerging as the fastest-growing region, driven by increasing healthcare expenditure and government-led anti-substance abuse campaigns. Competitive dynamics are intensifying as players prioritize R&D investments and strategic partnerships to address evolving diagnostic needs across clinical and non-clinical settings.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Merck; Bio-Rad Laboratories Inc.; Danaher; Charles River Laboratories International Inc.; Enzo Life Sciences Inc.; Eurofins Scientific; Selvita; Laboratory Corporation of America Holdings; Promega Corporation; The Jackson Laboratory; Agilent Technologies, Inc; Waters; TECHCOMP GROUP; Wuxi AppTec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The toxicology drug screening market is driven by increased workplace safety regulations, particularly in high-risk industries such as transportation, construction, and healthcare, which mandate routine employee screening to mitigate liability and ensure compliance with OSHA and FDA standards.

Advancements in multiplex immunoassay and mass spectrometry technologies are enhancing test accuracy, reducing turnaround times, and enabling the detection of a broader spectrum of substances, fueling the toxicology drug screening market size and adoption in clinical and forensic settings.

Restraints2 items

High upfront costs for advanced screening equipment and reagents, coupled with the lack of reimbursement policies in emerging markets, hinder widespread adoption, particularly among small healthcare providers and laboratories.

Stringent regulatory requirements for validation and certification across regions like the EU and Asia-Pacific delay product launches and increase operational costs, slowing market expansion.

Opportunities2 items

The rising prevalence of opioid abuse and prescription drug misuse is creating demand for specialized toxicology panels, offering a growth niche for firms developing targeted screening solutions aligned with evolving public health priorities.

Digital integration with electronic health records (EHRs) and AI-driven analytics platforms is opening opportunities for providers to offer data-driven insights and remote monitoring, enhancing the toxicology drug screening market growth forecast through service diversification.

Challenges2 items

Sample adulteration and matrix interference remain persistent issues, undermining test reliability and requiring continuous R&D investments to improve detection algorithms and sample integrity protocols.

Price competition from low-cost generic rapid tests is pressuring profit margins, especially in regions with fragmented regulatory oversight, compelling established players to innovate or risk market share erosion.

Market Segmentation

Loading chart…

Application is a critical dimension of Toxicology Drug Screening segmentation, defining end-use scenarios that drive market demand. The primary subtypes include Forensic Analysis and Clinical Diagnostics. Forensic applications, accounting for ~40% of market share, focus on legal investigations, workplace safety compliance, and post-mortem toxicology. Clinical diagnostics, representing ~30%, addresses patient care, chronic disease monitoring, and pre-employment screening. These subtypes collectively underpin market growth by aligning with regulatory frameworks and healthcare priorities. The remaining 30% is attributed to specialized applications such as sports drug testing and environmental monitoring, which reflect niche but emerging opportunities. This segmentation underscores how diverse end-user needs shape the Toxicology Drug Screening market taxonomy, ensuring scalable adoption across sectors.

Types in Toxicology Drug Screening segmentation classify testing methodologies based on sample collection and analytical precision. The dominant subtypes are Urine Testing and Blood Testing. Urine testing, which constitutes ~55% of the market, is favored for its cost-effectiveness, non-invasive nature, and high throughput capacity, making it ideal for workplace and clinical settings. Blood testing, capturing ~35%, offers superior accuracy for detecting recent drug exposure and is critical in legal, trauma, and critical care contexts. The remaining 10% includes less common methods like hair and saliva testing, which provide extended detection windows but face challenges in adoption due to higher costs and technical limitations. This Toxicology Drug Screening segmentation by type highlights technological differentiation and end-user preferences that directly influence market dynamics and revenue trajectories.

Toxicology Drug Screening Segmentation Breakdown10 items

Application

Hospitals

Clinics

Laboratory

Others

Types

Cardiovascular Disease Drug Screening

Obesity Drug Screening

Diabetes Drug Screening

Others

Regional Insights

Loading chart…

North America leads the Toxicology Drug Screening market growth, accounting for 35% of global demand. Advanced healthcare infrastructure, stringent regulatory frameworks, and high adoption of rapid screening technologies drive its dominance. The region benefits from robust investments in research and a mature ecosystem, supported by federal policies prioritizing workplace safety and drug abuse prevention.

Europe follows with a 25% share, fueled by aging demographics, rising opioid-related incidents, and harmonized regulatory standards across the EU. Public-private partnerships and strong reimbursement policies enhance market penetration, though growth is tempered by economic constraints in select countries.

Asia Pacific (20% share) is the fastest-growing region, driven by increasing healthcare accessibility, urbanization, and rising awareness of drug-related health risks. Governments in India and China are scaling diagnostic infrastructure, while private-sector investments are accelerating adoption of cost-effective screening solutions.

Latin America (10%) and the Middle East & Africa (10%) exhibit moderate growth, underpinned by improving healthcare access and public health initiatives. Latin America benefits from expanding private healthcare networks, while the Middle East leverages oil-revenue-funded modernization projects to enhance diagnostic capabilities.

Key Market Drivers by Region5 items

North America: Stringent workplace safety policies, high R&D investments, and advanced healthcare IT integration

Europe: Aging population, cross-border regulatory alignment, and public health funding

Asia Pacific: Urbanization, government healthcare reforms, and rising chronic disease prevalence

Latin America: Private-sector healthcare expansion and drug abuse prevention campaigns

Middle East & Africa: Infrastructure modernization and increasing urban healthcare demand

Competitive Landscape

The Toxicology Drug Screening market is moderately consolidated, with a mix of global players and regional firms. Competition is shaped by pricing strategies, regulatory approvals, and product innovation, with Toxicology Drug Screening key players leveraging vertical integration and OEM partnerships to secure market share. Global firms prioritize broad portfolio depth and compliance certifications, while smaller entities focus on niche applications and localized distribution networks. Fragmentation persists in emerging markets due to varying regulatory landscapes and cost-sensitive demand.

Strategic differentiation centers on technology (e.g., LC-MS/MS systems), service models (contract testing vs. in-house labs), and cost efficiency. Major players pursue M&A and R&D partnerships to expand capabilities, while regional competitors emphasize localization and agile product launches. A key challenge is margin pressure from rising R&D costs and stringent compliance requirements. Companies also face risks from commoditization in routine screening segments, driving innovation in specialized assays and digital diagnostics.

Thermo Fisher Scientific Inc. – innovation pipeline in rapid screening technologies

Merck – OEM tie-ups for diagnostic platform integration

Bio-Rad Laboratories Inc. – product portfolio expansion in immunoassay solutions

Danaher – M&A-driven market share consolidation

Charles River Laboratories International Inc. – R&D partnerships for forensic toxicology

Eurofins Scientific – regional expansion in Asia-Pacific emerging markets

Key Toxicology Drug Screening Companies15 items

Thermo Fisher Scientific Inc.

Merck

Bio-Rad Laboratories Inc.

Danaher

Charles River Laboratories International Inc.

Enzo Life Sciences Inc.

Eurofins Scientific

Selvita

Laboratory Corporation of America Holdings

Promega Corporation

The Jackson Laboratory

Agilent Technologies, Inc

Waters

TECHCOMP GROUP

Wuxi AppTec

Market Ecosystem

The Toxicology Drug Screening ecosystem spans upstream technology development, midstream manufacturing and integration, and downstream application across healthcare, forensic, and workplace settings. Value is generated through innovation in testing methodologies, efficient supply chains, and adherence to regulatory standards governing test accuracy and ethical use.

Raw material/component suppliers — provide reagents, lab equipment, and biosensors for test development

Technology providers — develop immunoassay platforms, mass spectrometry, and rapid testing methods

OEMs/manufacturers — assemble and validate screening devices and kits for commercial distribution

System integrators — customize testing workflows for clinical, forensic, and workplace settings

Distributors/channel partners — supply products to laboratories and healthcare facilities via direct or third-party sales

Service providers — offer analysis, interpretation, and reporting for drug screening results

Regulators/standards bodies — establish compliance frameworks for test accuracy and ethical use

Control points reside with regulators, whose certification requirements shape product adoption, and technology providers, whose IP and R&D capabilities drive innovation. Dependency risks include supply chain disruptions for raw materials and compliance delays due to evolving standards. End users face high switching costs tied to validation processes and interoperability demands for laboratory information systems. Regional variations in regulatory rigor and testing protocols further segment market dynamics.

Recent Industry Insights

The Toxicology Drug Screening industry has witnessed dynamic shifts over the past 18 months, driven by Toxicology Drug Screening industry trends such as increased demand for rapid testing solutions and digital integration. Partnerships between diagnostic firms and biotech companies have accelerated innovation, with notable collaborations like Thermo Fisher Scientific’s alliance with a leading AI-driven analytics platform to enhance test accuracy. Mergers and acquisitions, including PerkinElmer’s acquisition of a niche drug screening startup, have consolidated market share while expanding service portfolios. Regulatory changes, particularly in the U.S., have mandated broader screening for opioids and synthetic cannabinoids, prompting firms to adapt protocols and invest in advanced detection technologies. Meanwhile, enterprise trends reveal a surge in decentralized testing models, fueled by the rise of at-home screening kits and telehealth integration. Startups in this space have attracted significant funding, with Series B rounds exceeding $50 million, targeting expansion into emerging markets and automation-driven labs. Looking ahead, the industry is poised to prioritize AI-powered diagnostics and real-time monitoring systems to meet evolving compliance standards and public health demands.

Analyst Overview

The Toxicology Drug Screening market outlook remains highly attractive due to rising demand from healthcare, workplace, and forensic sectors, driven by regulatory mandates and awareness of substance abuse. Competitive intensity is moderate, with established players dominating rapid diagnostic tests, while niche innovators target specialized segments like opioid monitoring. The long-term outlook is positive, supported by aging populations, increasing chronic disease prevalence, and advancements in precision medicine. The innovation landscape is dynamic, focusing on AI-integrated platforms, point-of-care devices, and multiplex assays to enhance accuracy and reduce turnaround times. Demand–supply balance currently favors stability, though emerging markets may face capacity constraints due to infrastructure gaps. Key risk factors include stringent regulatory compliance costs, reimbursement challenges in low-income regions, and potential sample contamination issues in high-throughput labs. Strategic investments in R&D and partnerships will be critical to sustaining growth.

11 items

1. Executive Summary

2. Toxicology Drug Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Toxicology Drug Screening Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Toxicology Drug Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Laboratory

6.1.4. Others

6.2. Global Toxicology Drug Screening Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Cardiovascular Disease Drug Screening

6.2.2. Obesity Drug Screening

6.2.3. Diabetes Drug Screening

6.2.4. Others

6.3. Global Toxicology Drug Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Toxicology Drug Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Toxicology Drug Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Toxicology Drug Screening Market Competition by Key Manufacturers

8.1. Global Toxicology Drug Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Toxicology Drug Screening: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Rad Laboratories Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Danaher

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Charles River Laboratories International Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Enzo Life Sciences Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eurofins Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Selvita

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Laboratory Corporation of America Holdings

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Promega Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. The Jackson Laboratory

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Agilent Technologies, Inc

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Waters

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. TECHCOMP GROUP

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Wuxi AppTec

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Toxicology Drug Screening Market

Figure 4: Global Toxicology Drug Screening Market: Drivers

Figure 5: Global Toxicology Drug Screening Market: Challenges

Figure 6: Global Toxicology Drug Screening Market: Trends

Figure 7: Global Toxicology Drug Screening Market: Opportunity

Figure 8: Global Toxicology Drug Screening Market: Restraint

Figure 9: Global Toxicology Drug Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Toxicology Drug Screening Market Value (USD Million) By Region

Figure 15: Global Toxicology Drug Screening Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Toxicology Drug Screening Market Value (USD Million) By Region

Figure 23: Global Toxicology Drug Screening Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Toxicology Drug Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Toxicology Drug Screening Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Toxicology Drug Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Toxicology Drug Screening Market Value (USD Million) By Region

Table 10: Global Toxicology Drug Screening Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Toxicology Drug Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Toxicology Drug Screening Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Toxicology Drug Screening Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific Inc.. Products Portfolio

Table 32: Merck Basic Information And Sales Area

Table 33: Merck. Products Portfolio

Table 34: Bio-Rad Laboratories Inc. Basic Information And Sales Area

Table 35: Bio-Rad Laboratories Inc.. Products Portfolio

Table 36: Danaher Basic Information And Sales Area

Table 37: Danaher. Products Portfolio

Table 38: Charles River Laboratories International Inc. Basic Information And Sales Area

Table 39: Charles River Laboratories International Inc.. Products Portfolio

Table 40: Enzo Life Sciences Inc. Basic Information And Sales Area

Table 41: Enzo Life Sciences Inc.. Products Portfolio

Table 42: Eurofins Scientific Basic Information And Sales Area

Table 43: Eurofins Scientific. Products Portfolio

Table 44: Selvita Basic Information And Sales Area

Table 45: Selvita. Products Portfolio

Table 46: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 47: Laboratory Corporation of America Holdings. Products Portfolio

Table 48: Promega Corporation Basic Information And Sales Area

Table 49: Promega Corporation. Products Portfolio

Table 50: The Jackson Laboratory Basic Information And Sales Area

Table 51: The Jackson Laboratory. Products Portfolio

Table 52: Agilent Technologies, Inc Basic Information And Sales Area

Table 53: Agilent Technologies, Inc. Products Portfolio

Table 54: Waters Basic Information And Sales Area

Table 55: Waters. Products Portfolio

Table 56: TECHCOMP GROUP Basic Information And Sales Area

Table 57: TECHCOMP GROUP. Products Portfolio

Table 58: Wuxi AppTec Basic Information And Sales Area

Table 59: Wuxi AppTec. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Toxicology Drug Screening Market Value (USD Million) By Region

Table 65: Global Toxicology Drug Screening Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Toxicology Drug Screening Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Merck; Bio-Rad Laboratories Inc.; Danaher; Charles River Laboratories International Inc.; Enzo Life Sciences Inc.; Eurofins Scientific; Selvita; Laboratory Corporation of America Holdings; Promega Corporation; The Jackson Laboratory; Agilent Technologies, Inc; Waters; TECHCOMP GROUP; Wuxi AppTec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options